0000000001095122

AUTHOR

E. Manca

showing 3 related works from this author

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

2018

Background Albuminuria has been classically considered a marker of kidney damage progression in diabetic patients and it is routinely assessed to monitor kidney function. However, the role of a mild GFR reduction on the development of stage ≥3 CKD has been less explored in type 1 diabetes mellitus (T1DM) patients. Aim of the present study was to evaluate the prognostic role of kidney disease measures, namely albuminuria and reduced GFR, on the development of stage ≥3 CKD in a large cohort of patients affected by T1DM. Methods A total of 4284 patients affected by T1DM followed-up at 76 diabetes centers participating to the Italian Association of Clinical Diabetologists (Associazione Medici D…

AdultMaleNephrologymedicine.medical_specialtyendocrine system diseasesRenal function030209 endocrinology & metabolism030204 cardiovascular system & hematologylcsh:RC870-923Kidneyurologic and male genital diseasesGFR03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusmedicineHumansAlbuminuriaDiabetic kidney diseaseKidneyType 1 diabetesurogenital systembusiness.industryIncidence (epidemiology)Middle Agedlcsh:Diseases of the genitourinary system. Urologymedicine.diseasefemale genital diseases and pregnancy complicationsAlbuminuria Diabetic kidney disease GFR NephrologyDiabetes Mellitus Type 1medicine.anatomical_structureItalyNephrologyDisease ProgressionAlbuminuriaFemalemedicine.symptombusinessResearch ArticleFollow-Up StudiesGlomerular Filtration RateKidney disease
researchProduct

Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial

2022

Background and purpose: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials. Methods: This was a phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Participants diagnosed with definite, probable or probable laboratory-supported ALS were assigned to receive RNS60 or placebo administered for 24 weeks intravenously (375 ml) once a week and via nebul…

treatmentAmyotrophic Lateral Sclerosisplacebo-controlledNeurodegenerative DiseasesALS; clinical trial; placebo-controlled; randomized; treatmentclinical trialTreatment OutcomeNeurologyDouble-Blind MethodrandomizedQuality of LifeHumansSettore MED/26 - NeurologiaNeurology (clinical)ALSBiomarkers
researchProduct

Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study.

2016

Aims.In recent years several warnings have been issued by regulatory authorities on the risk of electrocardiogram abnormalities in individuals exposed to psychotropic drugs. As a consequence of these warnings, monitoring of the QT interval corrected for heart rate (QTc) has become increasingly common. This study was conducted to measure the frequency of QTc prolongation in unselected psychiatric patients, and to document the associated factors using a cross-sectional approach.Method.The study was carried out in 35 Italian psychiatric services that are part of the STAR (Servizi Territoriali Associati per la Ricerca) Network, a research group established to produce scientific knowledge by col…

AdultMalemedicine.medical_specialtyPsychotropic drugsEpidemiologymedicine.medical_treatmentLong QT syndromeAntidepressantDrug overdoseAdverse effectQT intervalAntipsychotic03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsPsychotropic drugmedicinePrevalenceHumanscardiovascular diseasesAntipsychoticAdverse effectPsychiatrySettore MED/25 - PsichiatriaPolypharmacybusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health; Environmental and Occupational Health; Psychiatry and Mental HealthOriginal Articlesmedicine.diseaseAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030227 psychiatrySubstance abuseLong QT SyndromeCross-Sectional StudiesItalyPsychiatry and Mental HealthPolypharmacyAripiprazoleFemalePublic HealthbusinessAntidepressant; adverse effect; antipsychotic; psychotropic drugsAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Adult; Antipsychotic Agents; Cross-Sectional Studies; Electrocardiography; Female; Humans; Italy; Long QT Syndrome; Male; Prevalence; Risk Factors; Polypharmacy; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsEpidemiology and psychiatric sciences
researchProduct